Top 100 Agencies: DiD

Share this article:
DiD work for the Tylenol Kids' Wellness Tracker App
DiD work for the Tylenol Kids' Wellness Tracker App

DiD's growth—from 35 full-timers at this time two years ago to 53 now, plus another dozen contractors who are in the office more than they're not—is, by most measures, a very good thing. But that sharp spike in business and headcount left everyone at the suburban Philly firm feeling cramped.

So in April the agency moved from one quirky workspace (a renovated hotel that DiD partner Peter Kenney calls “a rabbit warren of little rooms”) to another (a renovated power plant dating back to the 1880s). The old space had closed doors aplenty; the new one is all glass and open space, complete with 24-foot ceilings. “What we have now is something that's more reflective of our team approach,” Kenney says.

The new space has proximity to a big client—McNeil Consumer Healthcare is practically within shouting distance—and to mass transportation. “We overlook the train lines, which should help us in terms of attracting talent,” says managing director Patty Henhoeffer.

The office upgrade was one of several for-the-better changes that DiD has experienced over the last year or so. To ease the day-to-day management burden on Kenney and fellow partner Rick Sannem, DiD restructured and expanded its leadership team. It elevated three staffers into new roles: Elyse Cole (VP, strategy and strategic services), Bill Fay (director, client services) and Abby Galardi (director, creative services).

“There were a lot of things that weren't getting done because Rick and I were off working with clients,” Kenney admits. “These were three people who had gained loads of respect and were chomping at the bit for more responsibility. It was a logical transition.”

DiD expanded into new therapeutic areas. Endocyte became DiD's first client in the oncology space (on a drug for ovarian cancer). Interleukin Genetics gave the agency a foothold in personalized medicine (on a product that determines disposition for periodontal disease). Business came from WellSpring Pharmaceutical (for heartburn drug Gelusil) and homeopathic product supplier Similasan. Yeast infection drug Monistat returned after years away. “It kind of wandered back,” Kenney cracks.

DiD had frustrations as well. Owing to a conflict with client Bausch + Lomb, the firm no longer works with Alcon Canada. Its work on behalf of Biomers failed to evolve due to funding issues. “We invested a lot in some clients who never had the resources to execute anything,” is the way Kenney puts it.

Expansion into other therapeutic areas is on the to-do list, with Henhoeffer pointing to skin care and animal health as likely targets: “They seem the natural next step.” Kenney, for his part, hopes the relationship with McNeil will intensify even further. “That new consumer journey they're on, with social and search and so many other components—that's the type of assignment that really gets us going.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets